Tyra Biosciences reports Phase 2 success in low-risk bladder cancer, plans pivotal trial
read at Endpoints ↗Positive readoutPositive
Tyra Biosciences announced that its experimental therapy for low‑risk bladder cancer has produced encouraging results in a Phase 2 study.
The company said the data, released on Wednesday, represent a step toward challenging Johnson & Johnson’s offerings in this indication.
Based on the findings, Tyra plans to advance the candidate into a pivotal trial later this year.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Tyra claims Phase 2 win in bladder cancer, will advance drug to pivotal trial”
read at Endpoints ↗89 words · retrieved 15m ago
comments(0)
5-min edit window · permanent after that